ArticleBMC infectious diseases2026
Pediatric pulmonary and extrapulmonary tuberculosis: immunological and diagnostic perspectives.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric tuberculosis (TB) remains a significant global health issue due to its diagnostic complexity and paucibacillary nature. This study aimed to evaluate the clinical, diagnostic, and immunological characteristics of pulmonary TB (PTB) and extrapulmonary TB (EPTB) in children.
methodsA retrospective review was conducted on 88 pediatric TB cases (38 PTB, 50 EPTB) at a referral children’s hospital in Iran from 2020 to 2024. Diagnostic methods included nucleic acid amplification tests (NAATs), interferon-gamma release assay (IGRA), tuberculin skin test (TST), mycobacterial culture, and imaging studies such as chest X-ray (CXR) and computed tomography (CT). Flow cytometry was used to assess immune profiles.
resultsAmong the 88 pediatric TB cases included in the study, 82 (93%) were caused by Mycobacterium tuberculosis (MTB), while 6 cases (7%) were attributed to nontuberculous mycobacteria (NTM). EPTB accounted for the majority of cases (57%). Drug susceptibility testing of MTB showed 87% sensitivity to all antibiotics; rifampicin and isoniazid resistance were found in 10% and 4%, respectively. Diagnostic test results for PTB and EPTB caused by MTB showed that NAATs had the highest positivity rates (100% for PTB and 96% for EPTB). IGRA was positive in 47% of PTB and 25% of EPTB cases. TST showed high positivity for both groups (80% PTB, 75% EPTB). Culture results were positive in 67% of PTB and 76% of EPTB cases. CXR was positive in 82% of PTB and 55% of EPTB cases, and CT scans showed 86% positivity for PTB and 58% for EPTB. A significant difference in immune profiles was observed between PTB and EPTB patients. The EPTB group exhibited notably reduced levels of CD3⁺ and CD8⁺ T cells, along with elevated CD19⁺, CD16⁺, and myeloperoxidase (MPO) levels.
conclusionEPTB and PTB in children display distinct immunological patterns. PTB is characterized by a stronger T-cell response, whereas EPTB exhibits greater humoral immune activation and T-cell suppression. The distinct immunological profiles suggest that different immune pathways contribute to disease localization. Integrating molecular diagnostics and immune profiling can enhance early detection and guide better clinical management of childhood TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.